Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer

International Journal of Oncology

Volumn 28, Issue 1, 2006, Pages 95-101

  Hotakainen, Kristina ^a   Bjartell, A ^b   Sankila, A ^a   Jarvinen R ^a   Paju, A ^a   Rintala, E ^a   Haglund, C ^a   Stenman, U H ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder cancer; RT PCR; TATI; Trypsinogen

Indexed keywords

APROTININ; TRYPSINOGEN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; CELL TRANSFORMATION; COMPARATIVE STUDY; DISEASE COURSE; EPITHELIUM; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TRYPSINOGEN; URINARY BLADDER NEOPLASMS;

EID: 33644804552     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.1.95     Document Type: Article

References (35)

1. Stenman UH, Huhtala ML, Koistinen R and Seppälä M: Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 30: 53-57, 1982.
2. Huhtala ML, Pesonen K, Kalkkinen N and Stenman UH: Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 257: 13713-13716, 1982.
3. Kazal LA, Spicer DS and Brahinsky RA: Isolation of a crystalline trypsin inhibitor-anticoagulant proteim from pancreas. J Am Chem Soc 70: 3034-3040, 1948.
4. Stenman UH, Koivunen E and Itkonen O: Biology and function of tumor-associated trypsin inhibitor, TATI. [Review]. Scand J Clin Lab Inv Suppl 207: 5-9, 1991.
5. Diggle CP, Cruickshank S, Olsburgh JD, et al: Identification of genes up-regulated in urothelial tumors, The 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 163: 493-504, 2003.
6. Stenman U-H: Tumor-associated trypsin inhibitor. Clin Chem 48: 1206-1209, 2002.
7. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M and Ylikorkala O: Tumor-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 70: 1188-1190, 1994. (Pubitemid 24358961)
8. Venesmaa P, Stenman UH, Forss M, Leminen A, Lehtovirta P, Vartiainen J, et al: Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. Br J Obstet Gynaecol 105: 508-511, 1998.
9. Paju A, Jacobsen J, Rasmuson T, Stenman U-H and Ljungberg B: Tumor-associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 165: 959-962, 2001. (Pubitemid 32156331)
10. Kelloniemi E, Rintala E, Finne P, Stenman U-H and Group F: Tumor-associated trypsin inhibitor (TATI) as a prognostic marker during follow-up of bladder cancer. Urology 62: 249-253, 2003.
11. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, et al: Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 10: 4761-4768, 2004.
12. Paju A, Bjartell A, Zhang W-M, Nordling S, Borgström A, Hansson J, et al: Expression and characterization of trypsinogen Produced in the human male genital tract. Am J Pathol 157: 2011-2021, 2000.
13. Koivunen E, Huhtala ML and Stenman UH: Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 264: 14095-14099, 1989.
14. Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U, et al: Activation of type IV procollagenases by human tumor-associated trypsin- 2. J Biol Chem 272: 21067-21074, 1997.
15. Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, et al: Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer 86: 577-581, 2000. (Pubitemid 30249741)
16. Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A, et al: The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 84: 1363-1371, 2001. (Pubitemid 32522105)
17. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, et al: Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-13) and degrades type I collagen. Biochemistry 42: 5414-5420, 2003.
18. Bjartell A, Paju A, Zhang W-M, Gadaleanu V, Hansson J, Landberg G, et al: Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 64: 29-39, 2005.
19. Sobin LH asd Wittekind CH: TNM classification of malignant tumors. International union against cancer. Wiley-Liss, New York, p180, 1997.
20. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998.
21. Itkonen O, Koivunen E, Hurme M, Alfthan H, Schröder T and Stenman UH: Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 115: 712-718, 1990.
22. Osman S, Turpeinen U, Itkonen O and Stenman UH: Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 161: 97-106, 1993. (Pubitemid 223036616)
23. Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, et al: Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene 41: 305-310, 1986.
24. Yamamoto T, Nakamura Y, Nishide J, Emi M, Ogawa M, Mori T, et al: Molecular cloning and nucleotide sequence of human pancreatic secretory trypsin inhibitor (PSTI) cDNA. Biochem Biophys Res Commun 132: 605-612, 1985.
25. Bjartell A, Malm J, Moller C, Gunnarsson M, Lundwell A and Lilja H: Distribution and tissue expression of semenogelin I and II in man as demonstrated by in situ hybridization and immunocytochemistry. J Androl 17: 17-26, 1996.
26. Lukkonen A, Lintula S, von Boguslawski K, Carpen O, Ljungberg B, Landberg G, et al: Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer 83: 486-490, 1999.
27. Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N, Varthalitis J, et al: TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 19: 271-277, 1996.
28. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, et al: Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 199: 176-184, 2003.
29. Yamamoto H, Iku S, Itoh F, Tang X, Hosokawa M and Imai K: Association of trypsin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer 91: 1324-1331, 2001.
30. Hirahara F, Miyagi Y, Miyagi E, Yasumitsu H, Koshikawa N, Nagashima Y, et al: Trypsinogen expression in human ovarian carcinomas. Int J Cancer 63: 176-181, 1995.
31. Bernard-Perrone F, Carrere J, Renaud W, Moriscot C, Thoreux K, Bernard P, et al: Pancreatic trypsinogen I expression during cell growth and differentiation of two human colon carcinoma cells. Am J Physiol-Gastr L 274: 1077-1086, 1998.
32. Yamashita K, Mimori K, Inoue H, Mori M and Sidransky D: A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 63: 6575-6578, 2003. (Pubitemid 37322934)
33. Hirahara F, Miyagi E, Nagashima Y, Miyagi Y, Yasumitsu H, Koshikawa N, et al: Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. Gynecol Oncol 68: 162-165, 1998.
34. Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN and Trope CG: Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 169: 40-52, 1993.
35. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM and Theodorescu D: Profiling the evolution of human metastatic bladder cancer. Cancer Res 64: 7813-7821, 2004.